Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LMT
8. USO
9. META
10. TLT

Go back to Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
(NASDAQ: ERNA) Delayed: 3.76 -0.15 (3.84%)
Previous Close $3.91    52 Week High $ 
Open $4.04    52 Week Low $ 
Day High $4.08    P/E N/A 
Day Low $3.71    EPS $ 
Volume 33,602       

(NASDAQ: ERNA) Delayed: 3.76 -0.15 (3.84%)
Previous Close $3.91    52 Week High $ 
Open $4.04    52 Week Low $ 
Day High $4.08    P/E N/A 
Day Low $3.71    EPS $ 
Volume 33,602